Summit Therapeutics (SMMT) Total Current Liabilities (2018 - 2026)
Summit Therapeutics' (SMMT) quarterly Total Current Liabilities came in at $103.6 million in Q2 2026, up 71.68% YoY from $60.3 million in Q2 2025, and up 24.38% on a QoQ basis from $83.3 million in Q1 2026.
Summit Therapeutics (SMMT) Total Current Liabilities (2018 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 9 years of Total Current Liabilities data on file, last reported at $103.6 million in Q2 2026.
- Quarterly Total Current Liabilities rose 71.68% year-over-year to $103.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $103.6 million (up 71.68% YoY) and the FY2025 annual result came in at $73.0 million, up 74.91% from the prior year.
- Total Current Liabilities grew to $103.6 million in Q2 2026, from $83.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $140.2 million in Q2 2024 to a low of $11.9 million in Q2 2023.
- A 5-year average of $52.3 million and a median of $40.3 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 68.89% — and 2024, when it jumped 1074.82%.
- Tracing SMMT's Total Current Liabilities over 5 years: stood at $38.8 million in 2022, then sank by 47.39% to $20.4 million in 2023, then surged by 104.5% to $41.7 million in 2024, then soared by 74.91% to $73.0 million in 2025, then jumped by 41.89% to $103.6 million in 2026.
- The last three Total Current Liabilities figures came in at $103.6 million (Q2 2026), $83.3 million (Q1 2026), and $73.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 103.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 103.57 Mn |
| Mar 31, 2026 | 83.27 Mn |
| Dec 31, 2025 | 72.99 Mn |
| Sep 30, 2025 | 64.93 Mn |
| Jun 30, 2025 | 60.33 Mn |
| Mar 31, 2025 | 34.88 Mn |
| Dec 31, 2024 | 41.73 Mn |
| Sep 30, 2024 | 59.01 Mn |
| Jun 30, 2024 | 140.17 Mn |
| Mar 31, 2024 | 23.44 Mn |
| Dec 31, 2023 | 20.41 Mn |
| Sep 30, 2023 | 113.74 Mn |
| Jun 30, 2023 | 11.93 Mn |
| Mar 31, 2023 | 17.44 Mn |
| Dec 31, 2022 | 38.78 Mn |
| Sep 30, 2022 | 16.68 Mn |
| Jun 30, 2022 | 15.17 Mn |
| Mar 31, 2022 | 22.72 Mn |
| Dec 31, 2021 | 25.62 Mn |
| Sep 30, 2021 | 22.79 Mn |